Skip to main content
LBRX
NASDAQ Life Sciences

LB Pharmaceuticals Q3 Loss Widens to $59.1M as Material Weaknesses Remain Unremediated

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$38.09
Mkt Cap
$1.229B
52W Low
$14.317
52W High
$50.16
52W Position info
166% above low
Off High info
24% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LBRX has more than doubled off its 52-week low of $14.317.

Summary

LB Pharmaceuticals posted a $59.1M third-quarter loss on $51.5M of Phase 3 R&D, with $403.8M of cash funding operations past Q2 2029. At quarter-end, material weaknesses in internal control remained unremediated.


Key Events · Earnings and Guidance · LBRX

  • Q3 Loss Widens on Trial Costs

    For the three months ended September 30, 2026, net loss was $59.1M ($1.79 per share), versus $3.6M a year earlier; the nine-month net loss reached $129.7M.

  • R&D Spend Jumps to $51.5M

    Research and development expense rose to $51.5M from $2.4M in Q3 2025, driven by the Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression.

  • Material Weaknesses Unremediated

    Management concluded disclosure controls and procedures were not effective at September 30, 2026; the previously identified material weaknesses over segregation of duties and IT access had not been remediated, with remediation targeted by December 31, 2026.

  • Cash Runway Past Q2 2029

    Cash, cash equivalents and short-term investments totaled $403.8M at September 30, 2026, which management expects to fund operations beyond the second quarter of 2029.


Analysis · LBRX · Life Sciences

Cash burn is the headline for the quarter: R&D jumped to $51.5M from $2.4M a year ago as the Phase 3 NOVA-2 schizophrenia trial and the Phase 2 ILLUMINATE-1 bipolar depression trial ramp. Against that, the $403.8M cash pile funds operations beyond Q2 2029, past the NOVA-2 topline expected in the first half of 2027, so there is no near-term financing need. The offsetting negative is governance: management concluded disclosure controls were not effective at September 30, 2026 because the previously identified material weaknesses in segregation of duties and IT access were not remediated, and it only expects remediation by December 31, 2026. Until those controls are fixed, the reliability of reported numbers carries an overhang.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LBRX was trading at $38.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.32 to $50.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LBRX - Latest Insights

LBRX
Nov 05, 2026, 8:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $41.00 info
Change: +$2.91 (+8%) info
Market Cap: $1.296B info
LBRX
Nov 05, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $41.00 info
Change: +$2.91 (+8%) info
Market Cap: $1.296B info
LBRX
Oct 01, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $37.28
Real-time Price: $41.00 info
Change: +$3.72 (+10%) info
Market Cap: $1.296B info
LBRX
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.76
Real-time Price: $41.00 info
Change: -$5.76 (-12%) info
Market Cap: $1.296B info
LBRX
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.76
Real-time Price: $41.00 info
Change: -$5.76 (-12%) info
Market Cap: $1.296B info